Summary Vitamin D is hypothesized to suppress inflammation. We tested total and free vitamin D metabolites and their association with inflammatory markers. Interleukin-6 levels were lower with higher 25-hydroxyvitamin D. 1,25-dihydroxyvitamin D and free 25OHD associations mirrored those of 25OHD. However, associations for the two metabolites diverged for tumor necrosis factor alpha (TNF-α) soluble receptors. Introduction Vitamin D is hypothesized to suppress inflammation, and circulating 25-hydroxyvitamin D (25OHD) and inflammatory markers are inversely correlated. However, total serum 25OHD may not be the best indicator of biologically active vitamin D.
Introduction
Chronic low-grade inflammation is a contributor to ageassociated frailty, mortality, and morbidity, including osteoporosis [1] . Inflammatory markers such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) are implicated in the process of vascular calcification and regulation of bone remodeling [2, 3] and have been linked to incident fracture [4] and BMD loss [5] .
Vitamin D has direct effects on bone health and may also act on bone by modulating inflammation [6, 7] . We have recently shown that low 1,25(OH)2D and 25OHD are independently associated with hip fracture in older men, but only 25OHD was independently associated with BMD loss [8] . 1, 25(OH) 2 D 3 may also play a role in regulating both the inflammatory process and bone turnover. Decreased 1,25(OH) 2 D 3 levels may contribute to inhibition of bone formation and suppress activated T cells and cell proliferation, which may accelerate the inflammation process in those with conditions such as ankylosing spondylitis (AS) [9] .
In vitro and in vivo evidence suggests that the biologically active form of vitamin D, 1,25(OH) 2 D, has several immunomodulatory functions, including suppression of proinflammatory marker expression and regulation of immune cell activity [10] . Treatment of fibroblast cultures with 1, 25(OH) 2 D 3 inhibits IL-6 and interleukin-8 (IL-8) [11] . Vitamin D inhibits the activation of the TNF-α-converting enzyme and subsequent inflammation on multiple levels [10, 12, 13] . Studies of vitamin D and inflammatory diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus, suggest a role for vitamin D deficiency in inflammation [14] [15] [16] [17] . However, little is known about the relationship between inflammation and vitamin D in the general population.
The objective of this study was to examine associations of total and free circulating 25OHD and 1,25(OH) 2 D and vitamin D binding protein (DBP) with inflammatory markers that include C-reactive protein (CRP), IL-6, TNF-α, IL-6, and TNF-α soluble receptors and one anti-inflammatory cytokine, interleukin-10 (IL-10), in a cohort of older men.
Methods

Study design
The Osteoporotic Fractures in Men Study (MrOS) is a prospective observational cohort study designed to determine risk factors for osteoporosis and age-related medical conditions in men 65 years of age and older. This study is conducted at six centers in the USA: Birmingham, AL; Minneapolis, MN; Palo Alto, CA; Pittsburgh, PA; Portland, OR; and San Diego, CA. Participants were recruited by mailings to the Department of Motor Vehicles (DMV), voter registration and participant databases, community and senior newspaper features and advertisements, and targeted presentations, from March 2000 through April 2002. Exclusion criteria were (1) inability to walk without assistance from another person, (2) bilateral hip replacements, (3) inability to provide self-reported data, (4) residence not near a study site, (5) judged by an investigator to have a medical condition that would result in early death, (6) and inability to understand and sign informed consent [18, 19] .
Vitamin D measurements
Serum concentrations of both the inactive (25OHD) and active (1,25(OH) 2 D) forms of vitamin D were analyzed in a random sample of men from the baseline visit of the MrOS study. Additional assays were carried out to measure vitamin D binding protein (DBP), the major serum protein carrier of vitamin D metabolites. Assays were completed in December 2012 using stored serum collected at the MrOS baseline visit. At the baseline visit, fasting morning blood samples were collected; serum was separated immediately after phlebotomy and then stored at −70°C. All samples for total 25OHD remained frozen in foil-wrapped vials to reduce UV exposure until assay.
Measures for 25OHD 2 (derived from ergocalciferol) and 25OHD 3 (derived from cholecalciferol) were performed at the Mayo Clinic using mass spectrometry as previously described [20, 21] . Deuterated stable isotope (d3-25OHD) was added to a 0.2-mL serum sample as internal standard. 25OHD 2 , 25OHD 3 , and the internal standard were extracted using acetonitrile precipitation. Extracts were further purified online and analyzed by liquid chromatography/tandem mass spectrometry using multiple reaction monitoring. 25OHD 2 and 25OHD 3 were reported individually. The minimum detectable limit was 4 ng/mL for 25OHD 2 and 2 ng/mL for 25OHD 3 . Aliquots of a single serum pool were included in alternate assay runs. Using the pooled serum, the interassay coefficient of variation (CV) for 25OHD 3 was 4.4 %, and the intraassay CV was 4.9 %.
Total 1,25(OH) 2 D was measured at the University of Leuven in Belgium, using LC-MS/MS without derivatization [22] . The lower limit of quantitation (LLQ) was 4.3 pg/mL for 1,25(OH) 2 D 2 and 6 pg/mL for 1,25(OH) 2 D 3 . Interassay CVs of pooled serum at low and high serum concentrations, respectively, were 10.1 % for serum with mean concentration of 7.16 pg/mL and 5.9 % for serum with mean concentration of 55.8 pg/mL [22] .
DBP concentration in serum was measured by a two-site polyclonal ELISA (Genway Biotech, San Diego, CA) at the OHSU Clinical and Translational Research Institute laboratory. Intraassay CV was 3 %. Because no gold standard for DBP exists, we also measured DBP by a monoclonal ELISA (mELISA; R&D Systems, Minneapolis, MN) and by polyclonal radial immunodiffusion assay (Laboratory of Clinical and Experimental Endocrinology, KU Leuven, Belgium), which had intraassay CVs of 2-4 % [23] .
Free 25OHD concentrations were calculated using published mathematical models that incorporate serum concentrations of 25OHD, 1,25(OH) 2 D, DBP, and albumin. Primary analyses were performed with estimated free 25OHD that assumed constant binding affinity across GC genotypes; however, GC-genotype-specific affinity estimates were also calculated for comparison [24] .
Inflammatory markers
Cytokine assays were measured in MrOS baseline samples utilizing a random sampling scheme. The assays were completed between December, 2009, and August, 2010, using archived serum collected at baseline on 1530 MrOS men as part of a MrOS ancillary study. Cytokine measures used in this analysis include CRP, IL-6, TNF-α, tumor necrosis factor alpha soluble receptors (TNF-α-sRI, TNF-α-sRII), and IL-6 soluble receptor (IL6-sR). IL-10 was also measured as an anti-inflammatory measure.
All cytokine assays were performed at the Laboratory for Cytokine Biochemistry, University of Vermont. The samples were thawed at 37°C and briefly centrifuged. Three hundred microliters of serum was placed into one cryovial for testing of TNF-α, TNF-α-sRI and sRII, IL-10, and CRP. Approximately 230 μL was plated into two plates for IL-6 and IL-6sR. The plates were refrozen at −80°C until assaying. IL-6 was measured using a high-sensitivity ELISA (R&D Systems, Minneapolis, MN). The assay range is 0.16-12.0 pg/mL.
Interassay CVs range from 6.11 to 8.47 %. IL-6sR was measured using ELISA (R&D Systems, Minneapolis, MN). [25] The assay range is 3120-200,000 pg/mL. Interassay CVs range from 4.68 to 8.83 %. TNF-α was measured using the Human Serum CVD3 Multiplex Kit (Millipore Corp., Billerica, MA) which is run by flow cytometry on the BioRad BioPlex 200 Luminex instrument. The assay range is 0.13-2000 pg/mL. Interassay CVs range from 4.93 to 9.13 %. TNF-α-sRI and sRII were measured with an ELISA (R&D Systems, Minneapolis, MN). The normal range for TNF-α-sRI in serum is 479-966 pg/mL and for TNF-α-sRII in serum is 1003-3170 pg/mL. Interassay CVs range from 5.42 to 8.59 % for TNF-α-sRI and 2.87 to 3.54 % for TNF-α-sRII. CRP was measured using the BNII nephelometer from Dade Behring utilizing a particle enhanced immunonepholometric assay. The assay range is 0.16-1100 μg/mL. Expected values for CRP in normal, healthy individuals are ≤3 μg/mL. Interassay CVs ranged from 1.52 to 3.68 %.
Covariates
Demographic characteristics such as age, race/ethnicity, clinical site, and lifestyle factors including weekly alcohol consumption and smoking history were determined at baseline by questionnaire. Physical activity was assessed with the Physical Activity Score for the Elderly (PASE) [26] . Height (cm) was measured on Harpenden stadiometers, and weight (kilograms) was measured on standard balance beam or digital scales. Body mass index (BMI) was calculated as kilograms per meter squared (kg/m 2 ). Prevalent cardiovascular disease was defined as self-report of heart attack, congestive heart failure (CHF), or angina. Diabetes, stroke history, selfreported health, surgical removal of stomach/intestine, and RA at baseline were also from self-report. Participants brought in all medications that they used within the last 30 days. All prescription medications recorded by the clinics were stored in an electronic medications inventory database (San Francisco Coordinating Center, San Francisco, CA). Each medication was matched to its ingredient(s) based on the Iowa Drug Information Service (IDIS) Drug Vocabulary (College of Pharmacy, University of Iowa, Iowa City, IA) [27] .
Serum creatinine was measured using a variation of the Jaffe enzymatic method. Renal function was expressed as estimated glomerular filtration rate (eGFR) in per millimeter per minute per 1.73 m 2 using a standardized serum-creatininebased formula [28] . Total fat mass was measured from dualenergy X-ray absorptiometry (DXA) scans using Hologic QDR 4500 scanners (Hologic, Inc., Bedford, MA).
Statistical analysis
All vitamin D measurements were standardized by subtracting the mean from each value and dividing by the standard deviation to facilitate comparison across measures. Correlations among inflammatory markers and between the inflammatory markers and the vitamin D measures were assessed using Spearman's correlation coefficients. We used linear regression modeling with robust standard errors to examine the effect of standardized vitamin D measurements on each inflammatory marker. Although the inflammatory markers are right-skewed, least-squares regression methods perform well with 500 or more observations and provide 95 % confidence interval coverage for all regression coefficients [29] . Betas (β) and 95 % confidence intervals (CI) from the model are reported as mean difference in the inflammatory markers per standard deviation (SD) change in vitamin D measurements. To identify any nonlinear associations between each vitamin D measure and inflammatory marker, we examined loess plots. We created an inflammatory index by summing the number of pro-inflammatory markers in the highest quartile (CRP, IL-6, TNF-α, TNF-α-sRI, TNF-α-sRII, and IL-6sR). We then dichotomized this index into those having ≥2 inflammatory markers in the highest quartile in comparison with those having <2 inflammatory markers in the highest quartile [4] . Logistic regression modeling was used to obtain odds ratios (OR) and corresponding 95 % CI.
No nonlinear associations were detected between any vitamin D measurement and inflammatory marker. The base model included age, race, clinical site, and season. We used stepwise modeling with a probability of removal at >0.10, forcing the base model covariates of age, site, race, season, and the vitamin D measure into the model and to include all covariates that were significantly associated with each inflammatory marker. All covariates that were significantly associated with any inflammatory marker were included in the final model for all inflammatory markers. An age-squared term was added to each model to check for non-linear association with age. There are 35 associations of interest (five vitamin D metabolites by six inflammatory markers and one anti-inflammatory marker). Thus, we have added a footnote to our tables with a Bonferroni-adjusted p value of ≤0.001 (0.05/35 = 0.001).
All analyses were conducted using SAS 9.3 (Cary, NC) and STATA release 12 (StataCorp, College Station, TX).
Results
Description and correlations
Men with inflammatory markers and vitamin D measures (Fig. 1) had a mean age of 74 ± 6 years and mean BMI of 27 ± 4 kg/m 2 . Most (91 %) were non-Hispanic White, and 85 % reported excellent or good health status. Sixteen percent were taking NSAIDs, and 27 % reported a history of heart attack, CHF, or angina (Table 1) .
All correlations between inflammatory markers and vitamin D measures were weak. IL-6 was negatively correlated with total and free 25OHD and 1,25(OH) 2 Table 1 ).
Inflammatory marker associations with 25OHD and 1,25(OH) 2 D
There was a significant association between lower IL-6 and higher 25OHD (0.23 pg/mL lower IL-6 per SD increase in 25OHD, 95 % CI 0.07 to 0.38 pg/mL), and this was independent of 1,25(OH) 2 D and DBP (Table 2) . Mean TNF-α was 0.21 pg/mL lower per SD increase in 25OHD, but this association was not statistically significant (95 % CI −0.64 to 0.21 pg/mL). Results did not change after adjusting for 1, 25(OH) 2 D and DBP ( Table 2) .
Associations of IL-6 with 25OHD and 1,25(OH) 2 D were similar (Fig. 2) , but statistically significant only for 25OHD. Mean IL-6 levels were significantly lower per SD increase in 25OHD (−0.23 pg/mL per SD, 95 % CI −0.38 to −0.07) and remained significant after adjusting for 1,25(OH) 2 D and DBP. Mean IL-6 levels were lower by 0.20 pg/mL (95 % CI 0.0004 to 0.39 pg/mL lower) per SD increase in 1,25(OH) 2 D. This association was attenuated to after 25OHD and DBP adjustment and was no longer significant. (Fig. 3) . Average TNF-α soluble receptors I and II were significantly lower by −62.05 pg/mL (95 % CI 26.09 to 98.01 pg/ mL) for TNF-α-sRI and −88.83 pg/mL (95 % CI 30.64 to 147.02 pg/mL) for TNF-α-sRII) per SD increase in 1, 25(OH) 2 D. This association was strengthened with adjustment of 25OHD and DBP (Table 2) . TNF-α soluble receptors I and II were higher by 34.66 pg/mL (95 % CI −4.17 to 73.48 pg/ mL) and 38.32 pg/mL (95 % CI −31.14, 107.78 pg/mL) per SD increase in 25OHD. This association was also strengthened with 1,25(OH) 2 D and DBP adjustment ( Table 2) .
Odds of having ≥2 inflammatory markers in the highest quartile decreased by 25 % (95 % CI 3 to 42 % decrease) per SD increase in total 1,25(OH) 2 D and was slightly strengthened with 25OHD and DBP adjustment (Table 2 ). However, 25OHD itself was not associated with odds of having ≥2 inflammatory markers in the highest quartile.
Inflammatory marker associations with free 25OHD, free 1,25(OH) 2 D, and DBP Average CRP was significantly higher for each SD increase in DBP (1.11 μg/mL higher, 95 % CI 0.45 to 1.76 μg/mL higher) ( Table 3 ). This association did not change after adjusting for 25OHD and 1,25(OH) 2 D (Table 2) . Although there was a significant negative correlation between CRP and free 25OHD (r = −0.12, p < 0.05), there was no significant association in regression analysis (β = 0.16 μg/mL; p = 0.31) (Supplemental Table 1 and Table 3 ). Mean IL-6 levels were lower by 0.35 pg/ mL (95 % CI 0.15 to 0.55 pg/mL lower) for each SD increase in free 25OHD and by 0.22 pg/mL (95 % CI 0.04 to 0.39 pg/ (Table 3) .
CRP and TNF-α soluble receptors' associations with free measures of 25OHD and 1,25(OH) 2 D and DBP from other assays (mELISA (R&D Systems, Minneapolis, MN) and radioimmunodiffusion assay (RID)) were similar to the polyclonal ELISA (Genway Biotech, San Diego, CA) assay, but slightly weaker. The CRP-DBP associations were also somewhat weaker but still statistically significant. IL-6 associations were significant for the free D measures from the RID assay, though slightly weaker, but not significant for the free D measures from the mELISA assay (Supplemental Table 2 ). Use of GC-genotype-specific binding affinities, rather than constant affinities, in the free D estimating equations did not make a substantial difference in associations.
Discussion
In this study of older men, 25OHD and 1,25(OH) 2 D were negatively associated with IL-6 with similar magnitudes. On the other hand, associations with TNF-α soluble receptors were positive for 25OHD and negative for 1,25(OH) 2 D. DBP was positively associated with CRP and had a weak positive association with IL-6. Perhaps for this reason, free vitamin D Our results support the role of serum IL-6 as a marker of the proposed anti-inflammatory effects of vitamin D. The observed associations of 25OHD and IL-6 were consistent with previous reports in older Irish adults [30] , although we observed somewhat higher median IL-6 levels across the 25OHD range. The inverse correlation between IL-6 and both total and free forms of both vitamin D metabolites supports previous reports that this cytokine is a target for vitamin D within the immune system. This is supported by mechanistic studies [31] , for example, demonstrating that 1,25(OH) 2 D treatment in cell cultures inhibited p38 and lowered downstream production of IL-6 [32] .
CRP is also an established systemic marker of inflammation, but it was not associated with either 25OHD or 1, 25(OH) 2 D in our study but instead was associated with levels of their serum carrier, DBP. CRP was shown to be associated with 25OHD among older Irish adults [30] and with 1, 25(OH) 2 D 3 in AS patients [9] . But, CRP levels were much higher in those studies, while in MrOS, CRP remained low across the range of 25OHD and 1,25(OH) 2 D (<1.5 μg/mL). Similar to our results, adults in the Framingham Offspring Study had no difference in CRP by 25OHD concentration [33] . We can speculate that the association between CRP and DBP may reflect the potential impact of systemic inflammatory cytokines on liver production of DBP [34] , although a link between inflammation, CRP, and DBP has not been demonstrated in other studies [35] . Soluble TNF-α receptors are another important marker of inflammation in that they represent potential antagonists of TNF-α function. In this study, 25OHD was positively associated and 1,25(OH) 2 D was negatively associated with TNF-α SRI and II, suggesting dichotomous functions for the two vitamin D metabolites. We speculate that soluble TNF-α receptors may be an important novel target for 25OHD as an anti-inflammatory agent. Specifically, the upregulated TNF-α sRI and II may provide a sensitive mechanism by which localized conversion of 25OHD to 1,25(OH) 2 D can abrogate inflammatory TNF-α responses.
An alternative hypothesis for the negative correlations between inflammatory markers and vitamin D metabolites could be that circulating cytokines regulate serum vitamin D metabolites. The renal vitamin D-activating enzyme 1α-hydroxylase (CYP27B1) is mainly regulated by serum PTH and FGF23, but extra renal production of 1,25(OH) 2 D by CYP247B1 is known to be induced by inflammatory cytokines such as TNF-α [36] [37] [38] [39] . Further characterization of this novel component of vitamin D and inflammation will be important in future studies of vitamin D and inflammation in the elderly, especially in those with increased inflammatory disease activity such as RA patients [40] . This is the first study to compare multiple measures of vitamin D and their associations with inflammatory markers in older adults. While other studies have examined vitamin D metabolite levels in those with SLE and RA [14, 15] , the MrOS study represents a predominantly healthy older male population, non-Hispanic White population with a very low prevalence of RA (5 %). If 1,25(OH) 2 D is confirmed to be an independent predictor of inflammatory state, it may be a useful marker in supplementation studies and for clinical detection of vitamin D deficiency. In the current study, 1,25(OH) 2 D was more strongly associated than 25OHD with TNF-α soluble receptors and with having ≥2 inflammatory markers in the top quartile.
We note limitations in our study. A substantial barrier to interpretation of vitamin D and inflammation studies is the question of whether inflammation also affects vitamin D. Due to the cross-sectional, observational nature of this analysis, we are unable to address the directionality. It is possible that inflammation affects vitamin D, rather than the reverse. For example, a recent study of patients undergoing elective hip or knee surgery recruited from orthopedic outpatient clinics showed that orthopedic surgery patients had decreases in 25OHD 3 , 25(OH)D, and 1,25(OH) 2 D as a systemic inflammatory response [41, 42] . However, RCTs [6, [43] [44] [45] [46] and in vitro evidence also support a role for 1,25(OH) 2 D 3 on inflammation [12, 13, 24, 47] through inhibition of IL-6 and IL-8 synthesis [11] .
The choice of a composite inflammatory score is somewhat arbitrary, and there are multiple methods of computing a composite inflammatory score [48] . The method that we presented in this paper of examining those with two or more inflammatory markers in the top quartile has also been published previously and represents a more specific indicator of systemic inflammation than a high level of just one inflammatory marker [4, [49] [50] [51] .
As in any observational study, the possibility for residual confounding remains. The MrOS cohort is well characterized in terms of body composition and used an extensive medical history questionnaire and medication inventory to capture potentially confounding variables. In this analysis, we adjusted for multiple variables known or suspected to be associated with inflammatory disease and vitamin D status. However, misclassification and unmeasured confounders could still have blunted or magnified associations between vitamin D and inflammation.
Estimations and direct measurements of circulating free 25OHD are not as yet standardized, and there is no gold standard for either DBP or free 25OHD assays. This limits our ability to conclude whether free 25OHD or free 1,25(OH) 2 D can improve the prediction of inflammatory markers or their downstream effects on health outcomes. However, our inclusion of multiple DBP measures and their estimates of free vitamin D provides the most thorough analyses of this question to date and suggests that further studies of free 25OHD and its role in inflammation are warranted.
In conclusion, IL-6 associations with 25OHD have been consistent in several population-based and clinical studies, and we observed no added information in considering free 25OHD or 1,25(OH) 2 D. In contrast, we observed consistently divergent associations with TNF-α soluble receptors for these metabolites. Considering the importance of TNF-α action in osteoclastic maturation [7, 52, 53] , future studies of vitamin D should include investigations of the effects of each metabolite.
